126 related articles for article (PubMed ID: 37171952)
1. Clinical Characteristics of Elderly Patients with Diffuse Large B-cell Lymphoma and the Risk Factors Affecting Cardiotoxicity of Anthracycline.
Zhang L; Jing H; Wang L; Tang S; Wang J
Altern Ther Health Med; 2023 Jul; 29(5):358-363. PubMed ID: 37171952
[TBL] [Abstract][Full Text] [Related]
2. Study on influencing factors of anthracycline-induced subclinical cardiotoxicity in DLBCL patients administered (R)-CHOP.
Dong Q; Ou W; Wang M; Jiang T; Weng Y; Zhou X; Tang X
BMC Cancer; 2022 Sep; 22(1):988. PubMed ID: 36115970
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of anthracycline-based therapy in elderly patients with diffuse large B-cell lymphoma.
Davis CC; Cohen JB; Shah KS; Hutcherson DA; Surati MJ; Valla K; Panjic EH; Handler CE; Switchenko JM; Flowers CR
Clin Lymphoma Myeloma Leuk; 2015 May; 15(5):270-7. PubMed ID: 25704479
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and cardiac toxicity of different-dose pegylated liposomal doxorubicin in elderly patients with diffuse large B lymphoma.
Li L; Chen R; Zhou D; Sun J; Wang L; Zhu L; Shen H; Xie W; Ye X
Cancer Med; 2023 Feb; 12(4):4184-4194. PubMed ID: 36200320
[TBL] [Abstract][Full Text] [Related]
5. [Analysis of clinical characteristics, treatment and survival of elderly patients with large diffuse B-cell lymphoma].
Li CY; Yang P; Dong F; Tian L; Wan W; Zhao W; Li QH; Pang M; Zhen JF; Jing HM
Zhonghua Yi Xue Za Zhi; 2020 Nov; 100(42):3296-3302. PubMed ID: 33202490
[No Abstract] [Full Text] [Related]
6. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
7. Risk factors for cardiovascular events and mortality in patients diagnosed with diffuse large B-cell lymphoma and treated with anthracyclines.
Diamond A; Ayyappan S; Cao S; Tashtish N; Boughan K; Cooper B; Fu P; Caimi PF
Hematol Oncol; 2022 Oct; 40(4):626-636. PubMed ID: 35644011
[TBL] [Abstract][Full Text] [Related]
8. Factors affecting survival in elderly patients with diffuse large B-Cell lymphoma.
Ulu BU; Yiğenoğlu TN; Başcı S; Bakırtaş M; Şahin D; Darçın T; Yaman S; Bozan E; Seçilmiş S; Candır BA; Yıldız J; İskender D; Baysal NA; Çakar MK; Dal MS; Altuntaş F
Leuk Res; 2021 Nov; 110():106700. PubMed ID: 34481125
[TBL] [Abstract][Full Text] [Related]
9. [Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].
Liu P; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Yang JL; Yang S; Wen TY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2020 Mar; 42(3):234-241. PubMed ID: 32252203
[No Abstract] [Full Text] [Related]
10. Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial.
Xue K; Gu JJ; Zhang Q; Liu X; Wang J; Li XQ; Luo J; Hernandez-Ilizaliturri FJ; Fernandez SF; Czuczman MS; Cao J; Hong X; Guo Y
Oncotarget; 2016 May; 7(22):32519-31. PubMed ID: 27081036
[TBL] [Abstract][Full Text] [Related]
11. Anthracycline-induced cardiotoxicity in diffuse large B-cell lymphoma: NT-proBNP and cardiovascular score for risk stratification.
Ferraro MP; Gimeno-Vazquez E; Subirana I; Gómez M; Díaz J; Sánchez-González B; García-Pallarols F; Martínez L; Ble M; Molina L; Belarte LC; Abella E; Elosua R; Comín-Colet J; Salar A
Eur J Haematol; 2019 Jun; 102(6):509-515. PubMed ID: 30972815
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial.
Xu PP; Fu D; Li JY; Hu JD; Wang X; Zhou JF; Yu H; Zhao X; Huang YH; Jiang L; Liu F; Su LP; Chen ZW; Zeng QS; Chen JP; Fang MY; Ma J; Liu T; Song YP; Yu K; Li Y; Qiu LG; Chen XQ; Gu J; Yan JS; Hou M; Huang HY; Wang L; Cheng S; Shen Y; Xiong H; Chen SJ; Zhao WL
Lancet Haematol; 2019 Jun; 6(6):e328-e337. PubMed ID: 31126528
[TBL] [Abstract][Full Text] [Related]
13. A retrospective analysis of real-world outcomes of elderly Chinese patients with diffuse large B-cell lymphoma.
Liu P; Han Y; Jiang SY; He XH; Qin Y; Gui L; Zhou SY; Zhou LQ; Yang JL; Yang S; Wen TY; Shi YK
Chin Med J (Engl); 2019 Aug; 132(15):1807-1814. PubMed ID: 31335477
[TBL] [Abstract][Full Text] [Related]
14. Cumulative anthracycline exposure and risk of cardiotoxicity; a Danish nationwide cohort study of 2440 lymphoma patients treated with or without anthracyclines.
Baech J; Hansen SM; Lund PE; Soegaard P; Brown PN; Haaber J; Jørgensen J; Starklint J; Josefsson P; Poulsen CB; Juul MB; Torp-Pedersen C; El-Galaly TC
Br J Haematol; 2018 Dec; 183(5):717-726. PubMed ID: 30406945
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of Dexrazoxane (DRZ) in sarcoma patients receiving high cumulative doses of anthracycline therapy - a retrospective study including 32 patients.
Schuler MK; Gerdes S; West A; Richter S; Busemann C; Hentschel L; Lenz F; Kopp HG; Ehninger G; Reichardt P; Pink D
BMC Cancer; 2016 Aug; 16():619. PubMed ID: 27507014
[TBL] [Abstract][Full Text] [Related]
16. [Clinical features and outcomes of newly diagnosed follicular lymphoma concurrent with diffuse large B-cell lymphoma component].
Lin ZJ; Zha J; Yi SH; Li ZF; Ping LY; He XH; Yu HF; Zheng Z; Xu W; Chen FL; Xie Y; Chen BY; Zhang HL; Wang L; Ding KY; Li WY; Yang HY; Zhao WL; Qiu LG; Li ZM; Song YQ; Xu B
Zhonghua Xue Ye Xue Za Zhi; 2022 Jun; 43(6):456-462. PubMed ID: 35968587
[No Abstract] [Full Text] [Related]
17. Low incidence of cardiotoxicity in patients with non-Hodgkin lymphoma receiving EPOCH after prior anthracycline exposure.
Buege MJ; Drill E; Horwitz SM; LeVoir A; Pak T; Peterson TJ; Dao PH; Matasar MJ
Eur J Haematol; 2023 Jul; 111(1):96-102. PubMed ID: 36971022
[TBL] [Abstract][Full Text] [Related]
18. Clinical characteristics and outcomes in diffuse large B cell lymphoma patients aged 70 years and older: a single-center experience with a literature review.
Jung YH; Woo IS; Han CW
Korean J Intern Med; 2015 Sep; 30(5):684-93. PubMed ID: 26354063
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the effect of R-CHOP regimen of pegylated liposomal doxorubicin on elderly patients with stage Ⅲ-Ⅳ diffuse large B-cell lymphoma.
Zhou X; Wang Y; Li X
Pak J Pharm Sci; 2021 Nov; 34(6(Special)):2455-2459. PubMed ID: 35039259
[TBL] [Abstract][Full Text] [Related]
20. "Diffuse Large B-Cell Lymphoma in the Elderly: Real-World Outcomes From a Developing Country".
Jobanputra K; Nayak L; Jain H; Shet T; Epari S; Bonda VNA; Thorat J; Bagal B; Laskar S; Rangarajan V; Agrawal A; Gujral S; Khanna N; Goda JS; Sengar M
Clin Lymphoma Myeloma Leuk; 2022 Oct; 22(10):e898-e906. PubMed ID: 35810145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
